No title
BackgroundPreliminary results from the SNAP trial presented at ESCMID Global 2025 reported a high incidence (19.8%) of acute kidney injury (AKI) in patients treated with (flu)cloxacillin for Staphylococcus aureus bacteraemia (SAB).ObjectiveIn Sweden, cloxacillin is used at lower daily doses, and the risk of nephrotoxicity has not been assessed in this setting.MethodsWe retrospectively evaluated re
